国: シンガポール
言語: 英語
ソース: HSA (Health Sciences Authority)
Estradiol hemihydrate 1.55mg eqv Estradiol
MSD PHARMA (SINGAPORE) PTE. LTD.
G03AA14
1.50mg
TABLET, FILM COATED
ORAL
Prescription Only
Organon (Ireland) Ltd
2012-11-12
CCDS-MK8175A-T-042013 LRN : S-900121-NME2-TB-CCDS.2 RA 0601 SG S5 (REF 1.4) Zoely Film-coated tablets 1. NAME OF THE MEDICINAL PRODUCT Zoely 2.5 mg / 1.5 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION White active film-coated tablets: Each film-coated tablet contains 2.5 mg nomegestrol acetate and 1.5 mg estradiol (as hemihydrate). Yellow placebo film-coated tablets: The tablet does not contain active substances. Excipient: Each white active film-coated tablet contains 57.71 mg of lactose monohydrate. Each yellow placebo film-coated tablet contains 61.76 mg of lactose monohydrate. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Active film-coated tablets: white, round and coded ‘ne’ on both sides. Placebo film-coated tablets: yellow, round and coded ‘p’ on both sides. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Oral contraception. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology One tablet is to be taken daily for 28 consecutive days. Each pack starts with 24 white active tablets, followed by 4 yellow placebo tablets. A subsequent pack is started immediately after finishing the previous pack, without a break in daily tablet intake and irrespective of presence or absence of withdrawal bleeding. Withdrawal bleeding usually starts on day 2-3 after intake of the last white tablet and may not have finished before the next pack is started. See ‘Cycle control’ in section 4.4. Special populations _ _ _Renal impairment_ CCDS-MK8175A-T-042013 LRN : S-900121-NME2-TB-CCDS.2 RA 0601 SG S5 (REF 1.4) Zoely Film-coated tablets Although data in renal impaired patients are not 完全なドキュメントを読む